{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T20:36:23Z","timestamp":1720384583895},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T00:00:00Z","timestamp":1490918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Growth hormone (GH)-secreting pituitary adenomas represent an uncommon subset of pituitary neoplasms. Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) have been used as primary or adjuvant treatment. The purpose of this study is to report the long-term tumor control and toxicity from our institution and to perform a systematic literature review of acromegaly patients treated with FSRT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively reviewed all patients treated with FSRT (median dose 50.4 Gray [Gy], range 50.4\u201354 Gy) between 2005 and 2012 who had: 1) GH-secreting adenoma with persistently elevated insulin growth factor-1 (IGF-1) despite medical therapy and 2) clinical follow up &gt;3 years after FSRT. Patients were treated with modern FSRT planning techniques. Biochemical control was defined as IGF-1 normalization. Systematic review of the literature was performed for FSRT in acromegaly.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>With a median follow-up of 80 months, radiographic control was achieved in all 11 patients and overall survival was 100%. Long-term biochemical control was achieved in 10 patients (90.9%) with either FSRT alone (36.4%) or FSRT with continued medical management (45.5%). No patient experienced new hypopituitarism, cranial nerve dysfunctions, or visual deficits. Our systematic review found published rates of biochemical control and hypopituitarism vary, with uniformly good radiographic control and low incidence of visual changes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Adjuvant FSRT offered effective long-term biochemical control and radiographic control, and there was a lower rate of complications in this current series. Review of the literature shows variations in published rates of biochemical control after FSRT for acromegaly, but low incidence of serious toxicities.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npx002","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T20:14:27Z","timestamp":1491423267000},"page":"255-262","source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes of acromegaly treated with fractionated stereotactic radiation: case series and literature review"],"prefix":"10.1093","volume":"4","author":[{"given":"Ryan","family":"Rhome","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology (R.R., R.-D.S., S.G.) and Department of Neurosurgery (I.M.G.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1236, New York, NY 10029"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle M","family":"Germano","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (R.R., R.-D.S., S.G.) and Department of Neurosurgery (I.M.G.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1236, New York, NY 10029"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-Dih","family":"Sheu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (R.R., R.-D.S., S.G.) and Department of Neurosurgery (I.M.G.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1236, New York, NY 10029"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (R.R., R.-D.S., S.G.) and Department of Neurosurgery (I.M.G.), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1236, New York, NY 10029"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,3,31]]},"reference":[{"issue":"14","key":"2019072608403416300_CIT0001","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1056\/NEJM199004053221405","article-title":"Acromegaly","volume":"322","author":"Melmed","year":"1990","journal-title":"N Engl J Med"},{"issue":"4","key":"2019072608403416300_CIT0002","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11102-006-0409-4","article-title":"Acromegaly","volume":"9","author":"Scacchi","year":"2006","journal-title":"Pituitary"},{"issue":"3-4","key":"2019072608403416300_CIT0003","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000095530","article-title":"Acromegaly and the cardiovascular system","volume":"83","author":"Lombardi","year":"2006","journal-title":"Neuroendocrinology"},{"issue":"7","key":"2019072608403416300_CIT0004","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1210\/jcem.87.7.8643","article-title":"Early vascular alterations in acromegaly","volume":"87","author":"Brevetti","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019072608403416300_CIT0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2019072608403416300_CIT0006","first-page":"166","article-title":"Excess mortality in acromegaly","volume":"68","author":"Holdaway","year":"2007","journal-title":"Horm Res"},{"key":"2019072608403416300_CIT0007","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.pmbts.2015.10.015","article-title":"The modern criteria for medical management of acromegaly","volume":"138","author":"Frara","year":"2016","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"2","key":"2019072608403416300_CIT0008","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.nec.2006.04.001","article-title":"Clinical results of conformal radiotherapy and radiosurgery for pituitary adenoma","volume":"17","author":"Prasad","year":"2006","journal-title":"Neurosurg Clin N Am"},{"issue":"2","key":"2019072608403416300_CIT0009","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11154-008-9106-0","article-title":"Modern techniques for pituitary radiotherapy","volume":"10","author":"Minniti","year":"2009","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2019072608403416300_CIT0010","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.3171\/2010.7.FOCUS10170","article-title":"A systematic analysis of disease control in acromegaly treated with radiosurgery","volume":"29","author":"Yang","year":"2010","journal-title":"Neurosurg Focus"},{"issue":"4","key":"2019072608403416300_CIT0011","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1210\/jc.2013-3743","article-title":"Stereotactic radiosurgery for acromegaly","volume":"99","author":"Lee","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019072608403416300_CIT0012","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrendo.2010.4","article-title":"Role of stereotactic radiosurgery in the management of pituitary adenomas","volume":"6","author":"Castinetti","year":"2010","journal-title":"Nat Rev Endocrinol"},{"issue":"51","key":"2019072608403416300_CIT0013","first-page":"107","article-title":"Gamma Knife radiosurgery in pituitary adenomas: Why, who, and how to treat?","volume":"10","author":"Castinetti","year":"2010","journal-title":"Discov Med"},{"issue":"4","key":"2019072608403416300_CIT0014","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jc.2005-1616","article-title":"Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly","volume":"91","author":"Jenkins","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2019072608403416300_CIT0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1748-717X-8-18","article-title":"Long term toxicity and prognostic factors of radiation therapy for secreting and non-secreting pituitary adenomas","volume":"8","author":"Rieken","year":"2013","journal-title":"Radiat Oncol"},{"issue":"5","key":"2019072608403416300_CIT0016","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/0360-3016(93)90548-A","article-title":"Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines","volume":"27","author":"Shaw","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"2019072608403416300_CIT0017","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"2019072608403416300_CIT0018","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2265.2000.00967.x","article-title":"Stereotactic conformal radiotherapy for pituitary adenomas: technique and preliminary experience","volume":"52","author":"Jalali","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2019072608403416300_CIT0019","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ijrobp.2003.12.012","article-title":"Stereotactic conformal radiotherapy in patients with growth hormone-secreting pituitary adenoma","volume":"59","author":"Milker-Zabel","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2019072608403416300_CIT0020","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2265.2006.02506.x","article-title":"Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas","volume":"64","author":"Minniti","year":"2006","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2019072608403416300_CIT0021","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijrobp.2006.08.039","article-title":"Intensity-modulated radiotherapy for pituitary adenomas: the preliminary report of the Cleveland Clinic experience","volume":"67","author":"Mackley","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2019072608403416300_CIT0022","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/153303460700600304","article-title":"Fractionated stereotactic radiotherapy for pituitary adenomas following microsurgical resection: safety and efficacy","volume":"6","author":"McClelland","year":"2007","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"2019072608403416300_CIT0023","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11102-007-0002-5","article-title":"Treatment of acromegaly: is there still a place for radiotherapy?","volume":"10","author":"Jallad","year":"2007","journal-title":"Pituitary"},{"issue":"1","key":"2019072608403416300_CIT0024","first-page":"72","article-title":"Outcome of fractionated stereotactic radiotherapy in patients with pituitary adenomas resistant to conventional treatments: a 5.25-year follow-up study","volume":"73","author":"Schalin-J\u00e4ntti","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2019072608403416300_CIT0025","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1530\/EJE-09-1045","article-title":"Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit","volume":"162","author":"Roug","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2019072608403416300_CIT0026","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10143-010-0285-2","article-title":"Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature","volume":"34","author":"Sun","year":"2010","journal-title":"Neurosurg Rev"},{"issue":"1","key":"2019072608403416300_CIT0027","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.arcmed.2011.01.004","article-title":"Efficacy and safety of radiotherapy in acromegaly","volume":"42","author":"Gonz\u00e1lez","year":"2011","journal-title":"Arch Med Res"},{"issue":"8","key":"2019072608403416300_CIT0028","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2011.02682.x","article-title":"Acromegaly: presentation, morbidity and treatment outcomes at a single centre","volume":"65","author":"Anagnostis","year":"2011","journal-title":"Int J Clin Pract"},{"key":"2019072608403416300_CIT0029","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1748-717X-6-169","article-title":"Adjuvant or radical fractionated stereotactic radiotherapy for patients with pituitary functional and nonfunctional macroadenoma","volume":"6","author":"Weber","year":"2011","journal-title":"Radiat Oncol"},{"issue":"3","key":"2019072608403416300_CIT0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijrobp.2013.06.2057","article-title":"Long-term outcomes of fractionated stereotactic radiation therapy for pituitary adenomas at the BC Cancer Agency","volume":"87","author":"Kim","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2019072608403416300_CIT0031","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.jocn.2012.11.026","article-title":"Acromegaly: a single centre\u2019s experience of stereotactic radiosurgery and radiotherapy for growth hormone secreting pituitary tumours with the linear accelerator","volume":"20","author":"Wilson","year":"2013","journal-title":"J Clin Neurosci"},{"issue":"6","key":"2019072608403416300_CIT0032","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00066-014-0802-2","article-title":"Treatment of acromegaly patients with risk-adapted single or fractionated stereotactic high-precision radiotherapy: High local control and low toxicity in a pooled series","volume":"191","author":"Bostrom","year":"2015","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"2019072608403416300_CIT0033","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12020-015-0610-1","article-title":"Long-term results of fractionated stereotactic radiotherapy as third-line treatment in acromegaly","volume":"50","author":"Diallo","year":"2015","journal-title":"Endocrine"},{"issue":"2","key":"2019072608403416300_CIT0034","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4158\/EP15830.OR","article-title":"High-precision conformal fractionated Radiotherapy is effective in achieving remission in patients with acromegaly after failed transsphenoidal surgery","volume":"22","author":"Patt","year":"2016","journal-title":"Endocr Pract"},{"issue":"8","key":"2019072608403416300_CIT0035","doi-asserted-by":"crossref","first-page":"943","DOI":"10.4158\/EP14574.OR","article-title":"Radiotherapy versus radiosurgery in treating patients with acromegaly: a systematic review and meta-analysis","volume":"21","author":"Abu Dabrh","year":"2015","journal-title":"Endocr Pract"},{"issue":"5","key":"2019072608403416300_CIT0036","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0360-3016(01)01535-8","article-title":"Fractionated stereotactically guided radiotherapy and radiosurgery in the treatment of functional and nonfunctional adenomas of the pituitary gland","volume":"50","author":"Milker-Zabel","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2019072608403416300_CIT0037","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/cen.13129","article-title":"The ongoing challenge of discrepant GH and IGF-I results in the evaluation of treated acromegalic patients. A systematic review and meta-analysis","volume":"85","author":"Kanakis","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2019072608403416300_CIT0038","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0360-3016(93)90230-S","article-title":"Tolerance of cranial nerves of the cavernous sinus to radiosurgery","volume":"27","author":"Tishler","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nop\/article-pdf\/4\/4\/255\/29005658\/npx002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T08:41:45Z","timestamp":1564130505000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/4\/4\/255\/3096906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,31]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,3,31]]},"published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npx002","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12]]},"published":{"date-parts":[[2017,3,31]]}}}